Cargando…
Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies
Patients with non–Hodgkin lymphoma and chronic lymphocytic leukemia (NHL/CLL) elicit inadequate antibody responses after initial SARS-CoV-2 vaccination and remain at high risk of severe COVID-19 disease. We investigated IgG, IgA, and IgM responses after booster vaccination against recent SARS-CoV-2...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9833496/ https://www.ncbi.nlm.nih.gov/pubmed/36644323 http://dx.doi.org/10.1158/2767-9764.CRC-22-0471 |
_version_ | 1784868253520101376 |
---|---|
author | Chang, Andres Akhtar, Akil Lai, Lilin Orellana-Noia, Victor M. Linderman, Susanne L. McCook-Veal, Ashley A. Switchenko, Jeffrey M. Saini, Manpreet Valanparambil, Rajesh M. Blum, Kristie A. Allen, Pamela B. Lechowicz, Mary Jo Romancik, Jason T. Ayers, Amy Leal, Alyssa O'Leary, Colin B. Churnetski, Michael C. Baird, Katelin Kives, Melissa Wrammert, Jens Nooka, Ajay K. Koff, Jean L. Dhodapkar, Madhav V. Suthar, Mehul S. Cohen, Jonathon B. Ahmed, Rafi |
author_facet | Chang, Andres Akhtar, Akil Lai, Lilin Orellana-Noia, Victor M. Linderman, Susanne L. McCook-Veal, Ashley A. Switchenko, Jeffrey M. Saini, Manpreet Valanparambil, Rajesh M. Blum, Kristie A. Allen, Pamela B. Lechowicz, Mary Jo Romancik, Jason T. Ayers, Amy Leal, Alyssa O'Leary, Colin B. Churnetski, Michael C. Baird, Katelin Kives, Melissa Wrammert, Jens Nooka, Ajay K. Koff, Jean L. Dhodapkar, Madhav V. Suthar, Mehul S. Cohen, Jonathon B. Ahmed, Rafi |
author_sort | Chang, Andres |
collection | PubMed |
description | Patients with non–Hodgkin lymphoma and chronic lymphocytic leukemia (NHL/CLL) elicit inadequate antibody responses after initial SARS-CoV-2 vaccination and remain at high risk of severe COVID-19 disease. We investigated IgG, IgA, and IgM responses after booster vaccination against recent SARS-CoV-2 variants including Omicron BA.5 in 67 patients. Patients had lower fold increase and total anti-spike binding titers after booster than healthy individuals. Antibody responses negatively correlated with recent anti-CD20 therapy and low B-cell numbers. Antibodies generated after booster demonstrated similar binding properties against SARS-CoV-2 variants compared with those generated by healthy controls with lower binding against Omicron variants. Importantly, 43% of patients showed anti-Omicron BA.1 neutralizing antibodies after booster and all these patients also had anti-Omicron BA.5 neutralizing antibodies. Patients with NHL/CLL demonstrated inferior antibody responses after booster vaccination, particularly against Omicron variants. Prioritization of prophylactic and treatment agents and vaccination of patients and close contacts with updated vaccine formulations are essential. SIGNIFICANCE: Limited data exist on antibody responses against current SARS-CoV-2 variants after booster vaccination in patients with NHL/CLL. We showed inferior antibody responses against Omicron variants after booster vaccination in these patients but some generated anti-Omicron titers. This stresses the importance of vaccinating patients with updated formulations. |
format | Online Article Text |
id | pubmed-9833496 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Association for Cancer Research |
record_format | MEDLINE/PubMed |
spelling | pubmed-98334962023-03-24 Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies Chang, Andres Akhtar, Akil Lai, Lilin Orellana-Noia, Victor M. Linderman, Susanne L. McCook-Veal, Ashley A. Switchenko, Jeffrey M. Saini, Manpreet Valanparambil, Rajesh M. Blum, Kristie A. Allen, Pamela B. Lechowicz, Mary Jo Romancik, Jason T. Ayers, Amy Leal, Alyssa O'Leary, Colin B. Churnetski, Michael C. Baird, Katelin Kives, Melissa Wrammert, Jens Nooka, Ajay K. Koff, Jean L. Dhodapkar, Madhav V. Suthar, Mehul S. Cohen, Jonathon B. Ahmed, Rafi Cancer Res Commun Research Article Patients with non–Hodgkin lymphoma and chronic lymphocytic leukemia (NHL/CLL) elicit inadequate antibody responses after initial SARS-CoV-2 vaccination and remain at high risk of severe COVID-19 disease. We investigated IgG, IgA, and IgM responses after booster vaccination against recent SARS-CoV-2 variants including Omicron BA.5 in 67 patients. Patients had lower fold increase and total anti-spike binding titers after booster than healthy individuals. Antibody responses negatively correlated with recent anti-CD20 therapy and low B-cell numbers. Antibodies generated after booster demonstrated similar binding properties against SARS-CoV-2 variants compared with those generated by healthy controls with lower binding against Omicron variants. Importantly, 43% of patients showed anti-Omicron BA.1 neutralizing antibodies after booster and all these patients also had anti-Omicron BA.5 neutralizing antibodies. Patients with NHL/CLL demonstrated inferior antibody responses after booster vaccination, particularly against Omicron variants. Prioritization of prophylactic and treatment agents and vaccination of patients and close contacts with updated vaccine formulations are essential. SIGNIFICANCE: Limited data exist on antibody responses against current SARS-CoV-2 variants after booster vaccination in patients with NHL/CLL. We showed inferior antibody responses against Omicron variants after booster vaccination in these patients but some generated anti-Omicron titers. This stresses the importance of vaccinating patients with updated formulations. American Association for Cancer Research 2022-12-22 /pmc/articles/PMC9833496/ /pubmed/36644323 http://dx.doi.org/10.1158/2767-9764.CRC-22-0471 Text en © 2022 The Authors; Published by the American Association for Cancer Research https://creativecommons.org/licenses/by/4.0/This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license. |
spellingShingle | Research Article Chang, Andres Akhtar, Akil Lai, Lilin Orellana-Noia, Victor M. Linderman, Susanne L. McCook-Veal, Ashley A. Switchenko, Jeffrey M. Saini, Manpreet Valanparambil, Rajesh M. Blum, Kristie A. Allen, Pamela B. Lechowicz, Mary Jo Romancik, Jason T. Ayers, Amy Leal, Alyssa O'Leary, Colin B. Churnetski, Michael C. Baird, Katelin Kives, Melissa Wrammert, Jens Nooka, Ajay K. Koff, Jean L. Dhodapkar, Madhav V. Suthar, Mehul S. Cohen, Jonathon B. Ahmed, Rafi Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies |
title | Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies |
title_full | Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies |
title_fullStr | Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies |
title_full_unstemmed | Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies |
title_short | Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies |
title_sort | antibody binding and neutralization of live sars-cov-2 variants including ba.4/5 following booster vaccination of patients with b-cell malignancies |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9833496/ https://www.ncbi.nlm.nih.gov/pubmed/36644323 http://dx.doi.org/10.1158/2767-9764.CRC-22-0471 |
work_keys_str_mv | AT changandres antibodybindingandneutralizationoflivesarscov2variantsincludingba45followingboostervaccinationofpatientswithbcellmalignancies AT akhtarakil antibodybindingandneutralizationoflivesarscov2variantsincludingba45followingboostervaccinationofpatientswithbcellmalignancies AT laililin antibodybindingandneutralizationoflivesarscov2variantsincludingba45followingboostervaccinationofpatientswithbcellmalignancies AT orellananoiavictorm antibodybindingandneutralizationoflivesarscov2variantsincludingba45followingboostervaccinationofpatientswithbcellmalignancies AT lindermansusannel antibodybindingandneutralizationoflivesarscov2variantsincludingba45followingboostervaccinationofpatientswithbcellmalignancies AT mccookvealashleya antibodybindingandneutralizationoflivesarscov2variantsincludingba45followingboostervaccinationofpatientswithbcellmalignancies AT switchenkojeffreym antibodybindingandneutralizationoflivesarscov2variantsincludingba45followingboostervaccinationofpatientswithbcellmalignancies AT sainimanpreet antibodybindingandneutralizationoflivesarscov2variantsincludingba45followingboostervaccinationofpatientswithbcellmalignancies AT valanparambilrajeshm antibodybindingandneutralizationoflivesarscov2variantsincludingba45followingboostervaccinationofpatientswithbcellmalignancies AT blumkristiea antibodybindingandneutralizationoflivesarscov2variantsincludingba45followingboostervaccinationofpatientswithbcellmalignancies AT allenpamelab antibodybindingandneutralizationoflivesarscov2variantsincludingba45followingboostervaccinationofpatientswithbcellmalignancies AT lechowiczmaryjo antibodybindingandneutralizationoflivesarscov2variantsincludingba45followingboostervaccinationofpatientswithbcellmalignancies AT romancikjasont antibodybindingandneutralizationoflivesarscov2variantsincludingba45followingboostervaccinationofpatientswithbcellmalignancies AT ayersamy antibodybindingandneutralizationoflivesarscov2variantsincludingba45followingboostervaccinationofpatientswithbcellmalignancies AT lealalyssa antibodybindingandneutralizationoflivesarscov2variantsincludingba45followingboostervaccinationofpatientswithbcellmalignancies AT olearycolinb antibodybindingandneutralizationoflivesarscov2variantsincludingba45followingboostervaccinationofpatientswithbcellmalignancies AT churnetskimichaelc antibodybindingandneutralizationoflivesarscov2variantsincludingba45followingboostervaccinationofpatientswithbcellmalignancies AT bairdkatelin antibodybindingandneutralizationoflivesarscov2variantsincludingba45followingboostervaccinationofpatientswithbcellmalignancies AT kivesmelissa antibodybindingandneutralizationoflivesarscov2variantsincludingba45followingboostervaccinationofpatientswithbcellmalignancies AT wrammertjens antibodybindingandneutralizationoflivesarscov2variantsincludingba45followingboostervaccinationofpatientswithbcellmalignancies AT nookaajayk antibodybindingandneutralizationoflivesarscov2variantsincludingba45followingboostervaccinationofpatientswithbcellmalignancies AT koffjeanl antibodybindingandneutralizationoflivesarscov2variantsincludingba45followingboostervaccinationofpatientswithbcellmalignancies AT dhodapkarmadhavv antibodybindingandneutralizationoflivesarscov2variantsincludingba45followingboostervaccinationofpatientswithbcellmalignancies AT sutharmehuls antibodybindingandneutralizationoflivesarscov2variantsincludingba45followingboostervaccinationofpatientswithbcellmalignancies AT cohenjonathonb antibodybindingandneutralizationoflivesarscov2variantsincludingba45followingboostervaccinationofpatientswithbcellmalignancies AT ahmedrafi antibodybindingandneutralizationoflivesarscov2variantsincludingba45followingboostervaccinationofpatientswithbcellmalignancies |